Patterns of biotechnology financing have undergone subtle shifts in recent months, and the shifts are an indication that the industry is moving from childhood into adolescence. Once the central source of support for U.S. biotechnology, venture capital has become somewhat less important, while tax-saving R&D limited partnerships are on the rise, and the trickle of public stock offerings has become a torrent. Around the world, but especially in Europe, governments are encouraging indigenous efforts in biotechnology. Many are backing up their encouragement with cash.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
This article is based on contributions by Vivian Lee, John Gurnsey, and Arthur Klausner, with additional material supplied by Ross Butler, Patricia Ann Duncan, Don Herichsen, Laura Mazur, Michael Stone, and Anne Zotov. It was edited by Tabitha M. Powledge.
Rights and permissions
About this article
Cite this article
Lee, V., Gurnsey, J. & Klausner, A. New Trends in Financing Biotechnology. Nat Biotechnol 1, 544–559 (1983). https://doi.org/10.1038/nbt0983-544
Issue Date:
DOI: https://doi.org/10.1038/nbt0983-544